MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs
Rhea-AI Summary
MiNK Therapeutics (NASDAQ: INKT) will report fourth quarter and full year 2025 financial results before market open on March 31, 2026 and host a conference call and webcast at 8:30 a.m. ET.
The company also highlighted platform expansion with a collaboration with C-Further and the University of Southampton to advance a PRAME-targeted, TCR-engineered iNKT cell therapy for pediatric cancers, citing non-dilutive funding and downstream commercial revenue potential.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – INKT
On the day this news was published, INKT gained 4.93%, reflecting a moderate positive market reaction. Argus tracked a peak move of +4.9% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $47.48M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
INKT fell 6.37% while close peers were mixed: ACET -2.18%, ARTV -1.68%, but ALXO +4.00%, HOWL +3.05%, PRLD +0.30%, indicating stock-specific pressure rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 10 | Strategic collaboration | Positive | +29.3% | Announced C-Further collaboration on PRAME-targeted TCR-engineered iNKT therapy. |
| Mar 10 | Partner program launch | Positive | +29.3% | C-Further unveiled PRAME-targeted allogeneic iNKT program with MiNK involvement. |
| Feb 03 | New translational data | Positive | +2.2% | Presented allo-iNKT IPF data supporting disease-modifying potential at Keystone Symposia. |
| Jan 08 | Phase 1 trial start | Positive | -1.7% | Announced investigator-sponsored Phase 1 AgenT-797 trial for GvHD prevention. |
| Nov 20 | Preclinical tumor data | Positive | -1.3% | Reported MiNK-215 preclinical data showing potent anti-tumor and TME remodeling. |
Positive partnership and data updates often aligned with gains, while some positive clinical/preclinical milestones saw modest negative reactions.
Over the past several months, MiNK highlighted multiple advances in its iNKT platform. A collaboration with C-Further on PRAME‑targeted pediatric oncology coincided with a 29.28% move, and C-Further’s broader pediatric oncology announcement saw the same reaction on Mar 10, 2026. Earlier, new IPF translational data led to a smaller 2.18% rise. In contrast, a Phase 1 GvHD trial start and potent MiNK‑215 preclinical data on Jan 8, 2026 and Nov 20, 2025 drew slight declines, showing occasional divergence even on constructive updates.
Regulatory & Risk Context
An effective S-3 shelf filed on Nov 7, 2025 allows MiNK to offer up to $150,000,000 in securities, including an ATM program for up to $50,000,000 in common stock, providing financing flexibility for R&D and corporate purposes while introducing potential dilution if utilized.
Market Pulse Summary
This announcement sets expectations for MiNK’s March 31, 2026 earnings call, where management plans to pair Q4 and full-year 2025 results with updates on its iNKT platform and the new C-Further collaboration. Recent history shows meaningful moves around partnership news and mixed reactions to clinical updates. Investors may focus on cash runway, any commentary related to the existing $150,000,000 shelf and $50,000,000 ATM, and progress across clinical-stage and engineered cell therapy programs.
Key Terms
allogeneic medical
invariant natural killer t (inkt) cell therapies medical
tcr-engineered medical
non-dilutive funding financial
downstream commercial revenue financial
engineered cell therapy medical
platform expansion technical
AI-generated analysis. Not financial advice.
Recent milestones include strategic collaboration with C-Further to advance PRAME-targeted iNKT cell therapy for pediatric cancers, with meaningful downstream commercial revenue potential
NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Tuesday, March 31, 2026.
The company will host a conference call and webcast at 8:30 a.m. ET that morning to review financial results and provide a corporate update on clinical progress, platform expansion, and strategic initiatives across its iNKT cell therapy portfolio.
The update follows several recent corporate and development milestones, including MiNK’s newly announced collaboration with C-Further and the University of Southampton to advance a PRAME-targeted, TCR-engineered iNKT cell therapy for pediatric cancers. The collaboration brings non-dilutive funding, meaningful downstream commercial revenue potential, and further validation of MiNK’s iNKT platform in engineered cell therapy. The program expands MiNK’s presence across validated tumor antigens and underscores the broader therapeutic and strategic value of its clinically advanced, allogeneic iNKT platform.
The collaboration reflects MiNK’s strategy of expanding its iNKT platform across both clinical-stage programs and engineered cell therapy approaches targeting validated tumor antigens, while leveraging external partnerships to advance programs in a capital-efficient manner.
| Conference Participant Dial Information | |
| United States - New York | (646) 307-1963 |
| USA & Canada - Toll-Free | (800) 715-9871 |
| Conference ID - | 6761941 |
Webcast & Replay Information
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website following the event.
Live event link: https://edge.media-server.com/mmc/p/6xxeh8o5
Webcast Replay: https://investor.minktherapeutics.com/events-and-presentations
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies and precision immune modulators designed to restore immune balance and drive durable cytotoxic responses. MiNK’s proprietary iNKT platform bridges innate and adaptive immunity to address cancer, autoimmune disease, and immune collapse.
Its lead candidate, agenT-797, is an off-the-shelf, cryopreserved iNKT cell therapy currently in clinical trials for solid tumors, graft-versus-host disease (GvHD), and critical pulmonary immune failure. MiNK’s pipeline also includes TCR-based and neoantigen-targeted iNKT programs that enable tissue-specific immune activation. With a scalable manufacturing process and broad therapeutic potential, MiNK is advancing a new class of immune reconstitution therapies designed to deliver durable, accessible, and globally deployable treatments.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the potential, safety, clinical benefit, and development plans for agenT-797 and other iNKT-based therapies. These statements involve risks and uncertainties, including those described under “Risk Factors” in MiNK’s most recent SEC filings. MiNK undertakes no obligation to update these statements except as required by law.
Contacts
Investor Contact: 917-362-1370 | investor@minktherapeutics.com
Media Contact: 781-674-4428 | communications@minktherapeutics.com
Source: MiNK Therapeutics
